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Live viral vectors expressing foreign antigens have shown great promise as vaccines against viral diseases. However, safety concerns remain a
major problem regarding the use of even highly attenuated viral vectors. Using the rabies virus (RV) envelope protein as a carrier molecule, we
show here that inactivated RV particles can be utilized to present Bacillus anthracis protective antigen (PA) domain-4 in the viral membrane. In
addition to the RV glycoprotein (G) transmembrane and cytoplasmic domains, a portion of the RV G ectodomain was required to express the
chimeric RV G anthrax PA on the cell surface. The novel antigen was also efficiently incorporated into RV virions. Mice immunized with the
inactivated recombinant RV virions exhibited seroconversion against both RV G and anthrax PA, and a second inoculation greatly increased these
responses. These data demonstrate that a viral envelope protein can carry a bacterial protein and that a viral carrier can display whole polypeptides
compared to the limited epitope presentation of previous viral systems.
© 2006 Elsevier Inc. All rights reserved.Keywords: Vaccine; Anthrax; Rhabdovirus; Rabies; GlycoproteinIntroduction
Until recently infection with Bacillus anthracis, the
causative agent of anthrax had posed only a low risk, with
minimal natural occurrence in humans. However, the
development of B. anthracis as a bioterrorism tool with the
death of five people and the infection of at least seventeen
others in the U.S. (Jernigan et al., 2002) in 2001, has
underscored the danger of an anthrax attack. Existing⁎ Corresponding author. 233 South 10th Street, Suite 331 BLSB, Philadelphia,
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are insufficient.
The most lethal form of the disease, inhalation anthrax,
presents with general, flu-like symptoms, so that early
diagnosis is difficult. Prompt recognition of symptoms is
required for effective therapeutic treatment using antibiotics
or passive immunization following unknown exposure
(Sternbach, 2003). While passive immunization is effective
(Sawada-Hirai et al., 2004), the availability of immune sera is
highly limited and no approved therapeutic antibodies against
anthrax are currently available. Several antibiotics care
effective against B. anthracis, but, antimicrobial resistance
engineered into future bioterrorism-grade anthrax can be
envisioned. Moreover, antibiotics can eliminate the bacteria
but not the toxins that may already have been released. Thus,
vaccination is a highly practical alternative to post-exposure
treatment and eliminates the risk of infection.
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act as a tripartite system in which transport of the active
components, lethal and edema factors into the cell, is
facilitated by the binding component, protective antigen
(PA). PA binds to receptors on the cell surface and is cleaved
by cellular furin (Molloy et al., 1992) into a small subunit and
the larger 63-kDa constituent, PA63. Seven receptor-bound
PA63 units oligomerize to form a complex that binds with
lethal factor and edema factor and that passes into the
cytoplasm. Two receptors, ATR/TEM8 (Bradley et al., 2001)
and CMG2 (Scobie et al., 2003), bind PA and mediate
toxicity. PA is comprised of four distinct domains, with
receptor interactions occurring at sites within PA domain-4
(D4) and -2. The structure of the receptor binding ridge is
highly conserved, suggesting that ATR/TEM8 and CMG2
interact with PA in the same manner (Santelli et al., 2004).
Passive and active immunization indicates that protection is
mediated by humoral immune responses (Enserink, 2002; Pitt
et al., 2001; Welkos et al., 2001) and binding of PA to the cell
surface receptors can be prevented by anti-PA antibodies. Of
note, antibodies elicited by PA immunization can confer
protection against B. anthracis challenge (Beedham et al.,
2001; Ivins et al., 1992, 1998; Kobiler et al., 2002; Little
et al., 1997), and antibodies against epitopes within PA D4
also show protective capacity (Flick-Smith et al., 2002b;
Kasuya et al., 2005; Maynard et al., 2002).
An FDA-licensed vaccine against anthrax exists consisting
of a cell culture filtrate adsorbed onto aluminum hydroxide
(Bioport, 2002). However, several aspects of this product point
to need for development of a novel vaccine: (i) it is indicated
only for use in at-risk individuals; (ii) the material is difficult to
characterize (Turnbull, 2000); (iii) it requires six immunizations
within the first 1.5 years with annual boosters thereafter
(Bioport, 2002); and (iv) reactogenicity is reported in up to 35%
of patients (Bioport, 2002).
Additional vaccine strategies, most of which focus on PA, are
being pursued. These include DNA vaccines encoding PA
(Ferrari et al., 2004), as well as approaches using various
microorganism vectors to express PA, such as influenza (Li et al.,
2005), vaccinia virus (Iacono-Connors et al., 1991), adenovirus
(Tan et al., 2003), Venezuelan equine encephalitis virus-based
replicons (Lee et al., 2003) and a Salmonella enterica serovar
typhimurium live vaccine encoding domain four of PA (Galen
et al., 2004). The best-developed vaccine candidate is a recom-
binant PA (rPA) adsorbed to aluminum hydroxide (Keyserling
et al., 2004). Efforts to enhance the immunogenicity of rPA
include immunogenic formulations such as copolymers
(Coeshott et al., 2004) or microsphere encapsulation (Flick-
Smith et al., 2002a) or addition of adjuvants (Berthold et al.,
2005; Ivins et al., 1992, 1998; McBride et al., 1998).
Rabies virus is a promising vaccine vector able to induce
humoral and cellular immune responses efficiently to foreign
antigens (McGettigan et al., 2001a, 2001b; Schnell et al., 2000).
Because of low seroprevalence in the human population, RV is
an excellent viral vector candidate. Methods for engineering the
virus are well established, up to two foreign genes totaling
6.5 kb have been incorporated thus far, and foreign sequencesare stably maintained. RV grows to high titers in cell lines
approved for human vaccine production and manufacture is
economical. Our current RV vaccine vector is based on the
vaccine strain SAD-B19 used since 1983 as a live oral
immunogen to vaccinate wild life in Europe and Asia
(Schneider et al., 1988). To further increase safety, several
attenuating mutations have been introduced into these live viral
vectors (McKenna et al., 2003).
Inactivated RV has been used to vaccinate humans in the U.
S. since 1978 (Plotkin, 1980) and thus has a significant history
of safety (Haupt, 1999). Potent and long-lasting neutralizing
antibodies to the RV glycoprotein are generated by immuni-
zation with killed particles (Thraenhart et al., 1994). Strong
humoral responses to heterologous glycoproteins such as HIV-
1 envelope (McKenna et al., 2004; Schnell et al., 2000) and
HCV E1/E2 (Siler et al., 2002) are elicited by killed RV
particles incorporating the foreign proteins. The highly
repetitive and rigid organization of viruses and virus-like
particles is thought to maximally stimulate B cells (Fehr et al.,
1997; Jegerlehner et al., 2002). CD4+ T helper epitopes
provided by virus particles can also provide necessary signals
for B cell activation (Hooper et al., 1994).
Here, we generated several RV G-PA chimeras in which
either PA63 or PA D4 was fused to ectodomain (ED)
truncation mutants of RV G. One of these chimeras, D4-E51,
properly trafficked to the cell surface and was efficiently
incorporated into virus particles. Mice immunized with killed
SPBN-D4-E51 particles mounted high antibody titers against
B. anthracis PA. The response was dose-dependent and was
skewed toward Th2-associated antibodies. Lymphocyte prolif-
eration was also observed, in response to viral antigens and
anthrax PA. These results suggest that inactivated rabies virus
can serve as an immunostimulatory carrier for immunization
against pathogens such as anthrax.
Results
Rabies virus expressing anthrax PA63
Anthrax PA is an excellent target for an anthrax vaccine
because particular anti-PA antibodies can prevent entry of the
toxin into cells. Therefore, anthrax PA63, optimized for
human codon usage to ensure high expression levels, was
cloned into the RV vaccine vector pSPBN resulting in
pSPBN-PA63 (Fig. 1). Recombinant RV was recovered by
standard methods and expression of PA63 was confirmed by
immunostaining with anti-PA monoclonal antibody (Fig. 2,
panel B′). To analyze the immunogenicity of the recombinant
RV SPBN-PA63, five BALB/c mice were inoculated i.m. with
106 ffu and sera from immunized mice were analyzed by a
PA-specific ELISA 14 days after immunization. However, no
PA-specific antibodies were detected in any of the immunized
animals (data not shown). To determine whether surface
expression of anthrax PA might increase its immunogenicity
in the vaccinated host, we used the RV G ER translocation SS
in addition to the RV G TM and CD (Fig. 1). The gene
encoding the chimeric RV G-anthrax PA was introduced into
Fig. 1. Construction of recombinant RVs expressing anthrax PA63 or chimeric RVG/anthrax PA63 fusion protein. SpeI andHpaI restriction sites flanking the RVG ED
between RV G SS and TM were introduced into the RV G gene (A) and were the target to replace the RV G ED sequence with PA63, resulting in PA63-TC (C). BsiWI
and NheI sites (B) were used to insert PA63 into the SPBN vector (D).
346 M.E. Smith et al. / Virology 353 (2006) 344–356the RV vector pSPBN, resulting in pSPBN-PA63-TC. BSR
cells were infected with SPBN (Fig. 2, panels A, A′, A′′),
SPBN-PA63 (Fig. 2, panels B, B′, B′′) or SPBN-PA63-TCFig. 2. Immunofluorescence for protein expression and surface staining. BSR cells w
SPBN-PA63-TC (C, C′ Cʺ) at an MOI of 0.01 and fixed 48 h later with paraformalde
with a monoclonal antibody directed against PA (Panels A′′, B′′, C′′) or permeabiliz
(Panels A′, B′, C′) or RV N protein (Panels A, B, C).(Fig. 2, panels C, C′ C′′) at an MOI of 0.01 and fixed 48 h
later with paraformaldehyde. Infected cells were analyzed di-
rectly by immunofluorescence microscopy with a monoclonalere infected with SPBN (Panels A, A′, A′′), SPBN-PA63 (Panels B, B′, B′′) or
hyde. Infected cells were analyzed directly by immunofluorescence microscopy
ed with Triton X-100 for internal staining with an antibody against anthrax PA
347M.E. Smith et al. / Virology 353 (2006) 344–356antibody directed against PA (Fig. 2 panels A′′, B′′, C′′) or
permeabilized with Triton X-100 for internal staining with an
antibody against anthrax PA (Fig. 2 panels A′, B′, C′) or RV N
protein (Fig. 2 panels A, B, C). All cells were infected with RV
as indicated by a bright signal with an RV N-specific antibody.
Moreover, anti-PA monoclonal antibody detected the internal
expression of PA63 in both SPBN-PA63- or SPBN-PA63-TC-
infected cells. However, no expression of PA63 on the cell
surface was detected for either of the viruses expressing PA63
independent of the use of the RV G signal sequence.
Part of the RV G ED is required for surface expression of PA D4
To test the hypothesis that a lack of transport through the
ER and Golgi apparatus accounted for the lack of surface
expression, and that a portion of the RV G might support such
transport, we utilized different portions of the RV G ED in
addition to the TM and CD of RV G. We constructed five
different plasmids containing increasing portions of the RV G
ED in addition to anthrax PA. Based on previous research
indicating that D4 of anthrax PA is the most potent antigen to
induce protective antibodies, we used this 140-aa fragment
comprising the carboxy-terminal region of PA. Use of this
fragment allowed us to examine whether D4 flanked by the
RV G SS, TM and CD fails to be transported to the cell
surface as observed for PA63. The genes encoding RV G-
anthrax PA D4 fusion proteins containing 0, 51, 127, 210, or
439 amino acids of the RV ED were PCR-amplified and
introduced into an expression plasmid under the control of the
T7 RNA polymerase promotor (Fig. 3). The resulting
plasmids were designated pD4-ΔED, pD4-E51, pD4-E127,Fig. 3. Construction of plasmids containing D4 fused to various RV G ED fragments.
linked glycosylation are indicated. To construct chimeric RV G/anthrax PA fusion
membrane-proximal 51, 127 or 210 amino acids of the RV G ectodomain containi
reintroduced into D4-ΔED to generate D4-E51, D4-127 and D4-210, respectively (C
D4-E439 (F).pD4-E210, and pD4-E439. To evaluate the cell surface
expression of the recombinant RV G-D4 fusion proteins,
BSR cells were infected with recombinant vaccinia virus
expressing T7 RNA polymerase for one h, transfected with
5 μg of each of the five plasmids and 24 h later fixed in
paraformaldehyde, permeabilized, and immunostained with
anti-PA monoclonal antibody. A second set of transfected
cells was treated similarly but was not permeabilized. As
shown in Fig. 4A, all proteins were successfully expressed
(internal staining) in transfected cells, whereas significant
surface expression was detected only for recombinant protein
D4-E51 (surface staining). More quantitative analysis by
FACS (Fig. 4B) confirmed that only D4-E51 was expressed at
high levels on the cell surface, while surface expression for
pD4-pD4-E127 and pD4-E439 was detectable but at lower
levels than observed for pD4-E51. Western blotting analysis
of transfected cell lysates using antibodies directed against
anthrax PA or RV G CD (Fig. 4C) revealed chimeric RV G-
D4 proteins of the expected sizes of 21 kDa, 29 kDa, 37 kDa,
or 74 kDa for D4-ΔED, D4-E51, D4-E127, and pD4-E439
with both the PA- and the RV G CD-specific antibodies.
Interestingly, the RV G CD-directed antibody failed to detect
the D4-E210 fusion protein suggesting cleavage or degrada-
tion of the carboxy-terminus of this protein. The antibody
directed against the amino-terminal-located D4 of D4-E210
detected the protein but at a smaller than predicted size,
further indicating degradation. All recombinant fusion pro-
teins showed a diffuse migration pattern over a range of up to
20 kDa. Sequence analysis of PA indicates several potential
N- and O-glycosylation sites within D4, which might
contribute to the observed retarded migration.Panel A shows RV G protein is shown in panel A. The three potential sites of N-
proteins, the RV G ED was replaced with domain 4 of PA (D4-ΔED, B). The
ng one, two or three potential N-linked glycosylation sites, respectively, were
, D, E). The full-length RV G ectodomain was inserted into D4-ΔED resulting in
Fig. 5. Expression and incorporation of D4-E51 into RV particles. BSR cells
were infected with SPBN or SPBN-D4-E51 at an MOI of 1 and after 48 h cell
lysates were prepared, separated by SDS-PAGE, and transferred to a
nitrocellulose membrane (lanes 1–4). To analyze incorporation of D4-E51 into
RV virions, sucrose-purified SPBNor SPBN-D4-E51 particles were separated by
SDS-PAGE and transferred to a nitrocellulose membrane (lanes 5–8). Blots were
probed with either sera directed against the RV G CD (α-G-CD) or anti-PA
monoclonal antibody (α-PA).
Fig. 4. Analysis of chimeric RV G/anthrax PA fusion proteins. BSR cells were
infected with recombinant vaccinia virus expressing T7 TNA polymerase and
transfected overnight with pD4-ΔED, pD4-E51, pD4-E127, pD4-E210 or pD4-
E439. To analyze surface expression of the fusion proteins, transfected cells
were fixed in 3% paraformaldehyde and either permeabilized (internal staining)
with 1% Triton X-100 or left untreated (surface staining). Cells were stained
with mouse anti-PA monoclonal antibody followed by FITC-labeled donkey
anti-mouse and examined by fluorescence microscopy (A). For FACS analysis
of transfected cells was stained with mouse anti-PA followed by FITC-labeled
donkey anti-mouse, fixed with formaldehyde and analyzed by flow cytometry
(B). For Western blot analysis, lysates of transfected cells were prepared,
separated by SDS-PAGE, and transferred to a nitrocellulose membrane. Blots
were probed with either sera directed against the RV G CD (right panel) or anti-
PA monoclonal antibody (left panel).
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RV virions
The results above indicated the highest level of surface
expression for D4-E51, suggesting its suitability for incorpora-
tion into the RVenvelope. Thus, the gene encoding D4-E51 was
cloned into pSPBN resulting in pSPBN-D4-E51. Recombinant
RV was recovered and analyzed for expression of the transgene
in infected cells and composition of the recombinant virions.
Western blotting analysis (Fig. 5) of lysates from SPBN- or
SPBN-D4-E51-infected cells or sucrose-purified virions using
anti-PA (Fig. 5 lanes 3, 4, 7, and 8) or anti-RVGCD (Fig. 5 lanes
1, 2, 5, and 6) revealed D4-E51 in cells infected with SPBN-D4-
E51 or in purified SPBN-D4-E51 virions, whereas no signal wasobserved for SPBN (Fig. 5, lanes 3 and 7). As expected, the RV
G CD-specific antibody detected RV G for both viruses. An
additional protein migrating at the expected size for the D4-E51
was detected in the case of SPBN-D4-E51-infected cells or
SPBN-D4-E51 virions (Fig. 5, lanes 2 and 6).
Live and killed RV-based anthrax vaccines are immunogenic in
mice
The successful incorporation of D4-E51 into virions
enabled us to study the induction of anti-PA immune re-
sponses using both inactivated and live SPBN-D4-E51 in an
animal model. Three groups of five female Swiss Webster mice
were inoculated i.m. with 3 × 106 ffu SPBN-D4-E51, 50 μg
inactive SPBN-D4-E51, 3 × 106 ffu SPBN or 50 μg inactive
SPBN. Blood samples were obtained from all mice at 14 days
post-immunization and sera were analyzed by ELISA on plates
coated with rPA or RV G. As shown in Fig. 6B all immunized
mice seroconverted against RV G. Moreover, all mice primed
with inactivated or live SPBN-D4-E51 also mounted anthrax
PA-specific antibodies, which were not detected in sera from
mice immunized with SPBN. A second inoculation increased
the RV G-specific titers about 3-fold, whereas the anthrax PA-
specific ELISA titers were increased 10-fold, with no
significant differences in antibody titers between mice
immunized with live RV or inactivated RV virions (Fig. 6).
Several vaccine approaches that appear promising in mice
are difficult to reproduce in larger animals or humans due to the
large amount of antigen needed for immunization. Thus, we
performed a dose–response analysis using antigen in amounts
Fig. 6. Humoral immune response to live or inactivated SPBN-D4-E51. Groups of five mice were immunized i.m. with 50 μg of inactivated SPBN-D4-E51, 3 × 106 ffu
of live SPBN-D4-E51, 50 μg of inactivated SPBN, or 3 × 106 ffu of live SPBN at 0 and 21 days. Mice were bled 2 weeks after each immunization and sera was
analyzed by ELISA specific for anthrax PA (A) or RV G (B). Data represent the mean of triplicate dilutions prepared from pooled sera.
349M.E. Smith et al. / Virology 353 (2006) 344–356ranging from 50 μg to 5 ng. A mixture of 100 ng recombinant
PA and 100 ng of RV G was included as a control. Groups of
three mice were immunized with the respective antigen on days
0 and 21, bled 14 days post-immunization, and sera were
analyzed by RV G- and anthrax PA-specific ELISAs (Table 1).
All mice immunized with killed SPBN-D4-E51 in a range of
50 μg to 50 ng showed strong responses to RV G and anthrax
PA. Moreover, immunization with as little as 5 ng resulted in
antigen-specific seroconversion. In response to immunization
with rPA and RV G, mice mounted titers similar to the 5 ng dose
of SPBN-D4-E51. A second inoculation with the same vaccineused for priming significantly increased the PA and RV G
responses. In addition, antibodies levels in sera of mice
immunized twice with recombinant PA and RV G were
comparable to those in sera of mice immunized twice with
50 ng SPBN-D4-51. A separate experiment (experiment B in
Table 1) using the same antigens and schedule but with 5-fold
increased amounts of recombinant anthrax PA and RV G
showed similar results with the exception that the increased
amount of RV G protein induced higher antigen-specific
seroconversion. However, priming with 500 ng PA still resulted
in low PA-specific titers after priming.
Table 1
Antibody titers of mice immunized with different amounts of inactivated SPBN-D4-E51
Anti-PA response post-prime Anti-PA response post-boost
50 μg SPBN-D4-E51 A 13,575 (13,516–13,690) A >109,350
B 1856 (1201–3730) B 16,555 (9773–35,464)
5 μg SPBN-D4-E51 A 4768 (4616–4933) A >109,305
B 1240 (497–3467) B 24,622 (13,734–37,292)
500 ng SPBN-D4-E51 A 4801 (4678–5014) A 39,154 (37,879–40,564)
B 295 (129–1321) B 4405 (1617–12,566)
50 ng SPBN-D4-E51 A 1439 (1365–1544) A 14,397 (13,372–14,969)
B 456 (44–1492) B 655 (45–3905)
5 ng SPBN-D4-E51 A 130 (125–134) A 1114 (941–1389)
B <50 B 156 (50–431)
100 ng rPA A 115 (109–124) A 13,645 (13,067–14,199)
500 ng rPA B 451 (165–1183) B 109,155 (84,899–
142,221)
Anti-RV G post-prime Anti-RV G post-boost
50 μg SPBN-D4-E51 A >109,350* A >109,350*
B >109,350* B >109,350*
5 μg SPBN-D4-E51 A >109,350* A >109,350*
B >109,350* B >109,350*
500 ng SPBN-D4-E51 A 14,831 (14,252–15,262) A >109,350*
B 24,122 (11,858–39,938) B >109,350*
50 ng SPBN-D4-E51 A 13,698 (13,091–14,477) A 12,908 (12,748–13,218)
B 12,445 (11,809–12,938) B >109,350*
5 ng SPBN–D4–E5 A 2154 (1527–4216) A 145,056 (142,656–147,620)
B 868 (133–11,809) B 36,879 (9257–140,172)
100 ng RV G A 153 (140–171) A 86,546 (44,130–129,912)
500 ng RV G B 23,273 (10,681–89,647) B >109,350*
Geometric mean titer (range low–high).
Two independent experiments (A and B) were performed. Experiment A: groups of three mice were immunized i.m. with 50 μg, 5 μg, 500 ng, 50 ng or 5 ng of
inactivated SPBN-D4-E51 or with 100 ng RV G + 100 ng rPA at 0 and 21 days. Mice were bled 2 weeks after each immunization. Sera for each group were pooled
placed in triplicate ELISAwells and the geometric mean determined. Experiment B: mice were immunized and bled as in experiment A except that the protein group
was immunized with 500 ng RV G + 500 ng rPA. Sera from individual mice were run in ELISA and the geometric mean determined.
* All three mice yielded titers >109,350.
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cell-associated antibody response
To determine whether were differences in IgG subclasses
induced by our immunization approach, sera from the dose–
response immunization regimen used in experiment B above
were analyzed by a PA-specific ELISA for IgG1 and IgG2a. As
shown in Fig. 7, immunization with the killed particles elicited
predominantly IgG1, whereas immunization with “protein
only” resulted in a high level of IgG2a compared to IgG1.
Although Th2 cells are known to facilitate antibody production
it remains whether such cells underlie the potent seroconversion
after priming with inactivated virions.
Antigen-specific proliferative response after immunization with
SPBN-D4-E51
To analyze the memory immune responses elicited by
vaccination with this novel vaccine carrier, spleens of four 6-
to 8-week-old Swiss Webster mice either left unimmunized
(Fig. 8, open bars) or immunized i.m. with 50 μg of inactivated
SPBN-D4-E51 (Fig. 8, shaded bars) on days 0 and 21 were
harvested 4 weeks post-boost and Splenocytes were stimulated
with RV G, RV RNP, inactivated virions (SPBN) orrecombinant PA (see Materials and methods). In three out of
four immunized mice, the proliferative responses were greatly
increased after restimulation with RV-specific antigens,
whereas one mouse mounted no detectable response. Compar-
ison of the two groups showed that such responses differed 11-
fold for restimulation with inactivated RV particles (P < 0.07)
and 15-fold for RV RNP (P < 0.02). The immunized group
also responded to RV G (P < 0.15). Note the very substantial
proliferative responses (11-fold, P < 0.03) detected after
restimulation with recombinant anthrax PA, indicating that
such responses can also occurs in the absence of the RV
antigens.
Discussion
This report describes the development of a novel approach to
create a potential vaccine against anthrax using inactivated RV
as a carrier. Virus particles present surface antigens in a dense
and repetitive array that maximally stimulates B cell prolifer-
ation and antibody production (Zinkernagel, 2003). Addition-
ally, the virus particle can provide CD4+ T helper epitopes that
supply the required second signal for B cell activation
(Baumgarth, 2000). To incorporate these properties into vaccine
against anthrax, we generated an RV particle that displays the
Fig. 7. IgG subclass induced by immunization with inactivated SPBN-D4-E51 or recombinant anthrax PA. Sera from the same mice as described in Table 1 were
evaluated for anti-anthrax-PA-specific IgG1 and IgG2a responses by ELISA. Because no seroconversion was detected for 5 ng dose after priming for SPBN D4-E51,
these sera were not analyzed (n/a).
351M.E. Smith et al. / Virology 353 (2006) 344–356antigenic component of B. anthracis, engineering the RV G
such that PA is expressed on the surface of RV particles. While
virus particles expressing chimeras of heterologous glycopro-
teins have been produced, the generation of viruses expressing
viral glycoprotein-bacterial toxin fusion proteins is recent as
exemplified by the insertion of PA D4 in the influenza virusFig. 8. Lymphoproliferative responses after immunization with inactivated SPBN-D
unimmunized (open bars) or immunized i.m. with 50 μg of inactivated SPBN-D4-E51
Splenocytes were stimulated with RV G, RV RNP or rPA for 3 days or with inactiva
removed and pulsed with 1 μCi of [3H]-thymidine. The average of three replicate w
Numbers below each bar reflect individual mice. Statistical significance was determhemagglutinin (Li et al., 2005). RV G is a type I transmembrane
protein and exists in virus particles as a homotrimer (Gaudin et
al., 1992). The glycoproteins of RV and vesicular stomatitis
virus (VSV), closely related rhaboviruses, share 20% amino
acid homology and their ectodomains are predicted to have
similar three-dimensional structure (Whitt et al., 1991). Studies4-E51. Groups of four 6- to 8-week-old Swiss Webster mice were either left
(shaded bars) on days 0 and 21 and spleens were harvested 4 weeks post-boost.
ted virions (SPBN) for 8 days. At the indicated time point, 100 μl of cells was
ells is indicated in counts per minute (CPM) over background (medium only).
ined by Student's t test of the means of each group.
352 M.E. Smith et al. / Virology 353 (2006) 344–356of VSV demonstrate the requirement for trimer formation in the
endoplasmic reticulum for transport of VSV G to the cell
surface (Doms et al., 1987, 1988). Consistent with these
observations, our initial construct, PA-TC, as well as the D4-
ΔED lacking any of the RV G ectodomain, were not transported
to the cell surface. Additionally, it has been shown that
glycosylation of at least one site on the RV G ectodomain is
required for trimer formation and for cellsurface expression of
wild-type RV G (Shakin-Eshleman et al., 1992). For VSV G,
only the 12 membrane proximal amino acids of the ED are
required for trimer formation, cell surface expression and
subsequent virus incorporation (Robison and Whitt, 2000).
However, this cannot explain why RV G chimera D4-E51 was
successfully trafficked to the cell surface because this region of
the RV G ED does not contain potential glycosylation sites.
However, trimerization of the D4-E51 molecules or between
wild type RV G and D4-E51 might also be required for
transport, a possibility that awaits biochemical analyses.
While we were succeeded in expressing a chimeric RV
G/anthrax PA fusion protein on the cell surface, a concern
remains regarding transport of the chimeric glycoproteins
depending on the size of the foreign polypeptide. However,
our preliminary results using the entire PA63 (428 aa) as well as
heavy-chain 50 of botulinum neurotoxin A (436 aa) fused to the
E51 construct indicate excellent cell surface expression (Koser
and Schnell, unpublished). Together, our results show that RV G
is permissive for the fusion of large foreign protein fragments,
that virus particles can incorporate such a chimeric glycopro-
tein, and that such RV-based vectors are replication-competent.
It is well accepted that PA is the major the antigenic
component of the current anthrax vaccine (Bioport, 2002) and
most anthrax vaccines under development focus on PA. The
lack of a humoral response to our initial vaccine expressing
PA63 by live RV is not entirely surprising since the protein is
produced intracellularly and availability to stimulate B cells is
therefore probably low. We previously reported that the
nucleoprotein of SARS-CoV was not immunogenic in mice
when expressed by a similar RV vaccine vector, but high titers
of neutralizing antibodies were detected when the SARS-CoV
spike protein was expressed by RV (Faber et al., 2005). Even
though the reason for this might lie in the different
immunogenicity of the two SARS-CoV proteins, it appears
that proteins expressed on the cell surface and incorporated into
RV virions are more potent inducers of humoral responses than
are internally expressed proteins. This motion is supported by
the finding that a single immunization with RV induces strong
humoral responses against RV G but only modest responses
against the internal RV proteins (Foley et al., 2000).
In contrast, PA expressed on the surface of virus particles
induced potent humoral responses with either live or killed
SPBN-D4-E51 particles stimulating antibody production after
only a single dose. Note that several other approaches to anthrax
vaccination require multiple doses for induction of antibody
responses (Aulinger et al., 2005; Galen et al., 2004; Rhie et al.,
2003). This is consistent with our expectation that SPBN-D4-
E51 particles maximally stimulate B cells. RV G in wild type
virus comprises 24% of the virus mass (Flamand et al., 1993;Wunner, 1991). The chimeric glycoprotein D4-E51 was
incorporated, at best, equivalently to RV G. Thus, attributing
12% of the virus particle mass to the D4-E51 glycoprotein, a
dose of 7.5 μg of SPBN-D4-E51 contains an antigen dose
equivalent to 500 ng of rPA. We speculate that this 150-fold
decrease in SPBN-D4-E51 dose requirement is due to
presentation by the virus particle, consistent with studies
comparing the immunogenicity of proteins presented in a
soluble form disordered form versus proteins complexed to
viruses or virus-like particles (Eckhart et al., 1996; Fehr et al.,
1997, 1998).
In addition to maximally stimulating B cells upon prime, the
virus particle is expected to be a strong inducer of T cell help,
especially as compared to a monomeric recombinant protein.
The RV G and nucleocapsid possess CD4+ T helper epitopes
(Bunschoten et al., 1989; Ertl et al., 1991; Macfarlan et al.,
1984), and exposure of mice to RV ribonucleoprotein
significantly augments virus-neutralizing antibodies upon
subsequent introduction of RV (Hooper et al., 1994). For
anthrax, immunization with PA at antibody-sub-stimulating
levels primes for a more robust and rapid humoral response
upon boost as compared to without prime (Marcus et al., 2004).
As expected, boosting with a second dose of live or killed
SPBN-D4-E51 resulted in an increase in anti-PA and anti-RV G
titers. High antibody titers also resulted following boost with
rPA, but there was a clear difference in the IgG subclass.
Antibodies to PA, either induced by vaccination or passively
administered, confer protection against challenge (Beedham et
al., 2001; Ivins et al., 1998), so that stimulation of a Th2 type
response is desirable. Analogous to the case with AVA
(Semenova et al., 2004) and with rPA formulated in aluminum
hydroxide (Tan et al., 2003) the subclass distribution of sera
from mice immunized with 50 ng or more of SPBN-D4-E51
was primarily IgG1 indicating a Th2-biased response. By
contrast, the 5 ng dose of SPBN-D4-E51 as well as rPA
stimulated Th1-associated antibodies consistent with the notion
that IgG subclass response is dependent upon dose and context
of antigen presentation.
We have demonstrated that killed RV particles can serve as
immunostimulatory carrier molecules for display of foreign B
cell antigens. SPBN-D4-E51 recombinant particles were potent
inducers of humoral immune responses after even a single
inoculation, which might be especially important for pre-
exposure treatment, where rapid responses are required. The
observed immune responses are Th2-dominated, and immu-
nized mice showed potent memory responses. Our results
establish proof-of-concept in the design of the particle and the
ability to stimulate B-cell responses. The quality of the antibody
response in terms of in vitro protection and challenge awaits
subsequent studies.
Materials and methods
Plasmid construction and virus recovery
pGEM PA63 (GenBank accession number DQ190737)
contains the sequence encoding the Newcastle disease virus
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followed by the sequence encoding the translocation-deficient
form [K397D, D425K (Sellman et al., 2001)] of the 63-kDa
fragment of B. anthracis PA (anthrax PA, GenBank accession
number M22589, (Welkos et al., 1988). The PA63 gene was
optimized for human codon usage to ensure high expression
levels. All sequences were synthesized by non-template PCR
and inserted into the pGEM-T vector (Promega Inc.) at the
XbaI site.
The following PCR reactions were performed using VENT
polymerase (Biolabs Inc.) and the primers listed in Table 1 (see
Supplementary material).
PA63 was PCR-amplified from pGEM PA63 using primers
RP187 and RP188. The RV vector pSPBN (Morimoto et al.,
2001) and PCR product were digested with BsiWI and NheI and
ligated, resulting in plasmid pSPBN-PA63.
To construct a plasmid encoding PA63 flanked by the RV G
signal sequence (SS), CD and TM, the N-terminal 22 amino
acids of the RV G including the RV SS (19 aa) was PCR
amplified from pTIT-G (McGettigan et al., 2001b) using
primers RP77 and RP125 (PCR1). In a second PCR reaction,
the sequence encoding RV G TM and CD was amplified from
pTIT-G using the primers RP79 and RP80 (PCR2). PCR1 and
PCR2 products were digested with SpeI and ligated. The ∼300
base pair (bp) product was digested with XbaI and PstI, and
cloned in the XbaI- and PstI-digested pBS-SKII+ (Stratagene
Inc.). The resulting plasmid was designated pBS-STS. The
PA63 sequence was PCR-amplified from pGEM PA63 using
primers RP189 and RP190, digested with SpeI and HpaI, and
cloned into SpeI- and HpaI-cleaved pBS-STS. The resulting
plasmid was designated pPA63-TC. PA63-TC was digested
with BsiWI and XbaI and cloned into pSPBN, yielding
pSPBN-PA63-TC.
Anthrax PA D4 was amplified from pGEM PA63 using
primers RP293 and RP310, digested with AvrII and HpaI, and
cloned into pBS-STS to yield pD4-ΔED. To generate the D4-
RV G chimeric glycoproteins containing different portions of
the RV G ED (see Fig. 3), a series of RV G ED fragments was
amplified from pTIT-G using the reverse primer RP299 and
forward primers RP295, 296, 297 and 298 and plasmid pTIT-G.
The PCR products, as well as plasmid pD4-ΔED, were digested
with StyI and HpaI, and the different ED fragments were ligated
into pD4-ΔED, resulting in pD4-E439, pD4-E210, pD4-E127
and pD4-E51.
To construct the recombinant RV expressing D4-E51, pD4-
E51 and pSPBN were digested with BsiWI and NheI and the
D4-51 fragment ligated to pSPBN, resulting in pSPBN-D4-E51.
All recombinant viruses were recovered using published
methods (Foley et al., 2000).
Virus purification and inactivation
BSR cells were infected at a multiplicity of infection (MOI)
of 0.1 in Dulbecco's modified Eagle's medium (DMEM,
Mediatech, Inc.) supplemented with 10% fetal bovine serum
(FBS) and incubated for 2 h with frequent gentle agitation.
Cells were washed three times with phosphate-buffered saline(PBS) and OptiPro medium (Invitrogen, Inc.) was added. Virus
was harvested at 3 and 6 days post-infection. Supernatants
from the two harvests were pooled and clarified by
ultracentrifugation using an SW28 rotor at 22,000 RPM for
1 h at 4 °C. Pelleted material was resuspended in PBS
overnight at 4 °C. Beta-propiolactone (BPL, Sigma, Inc.)
diluted 1:100 in ice-cold dH2O was added to the virus solution
to a final BPL dilution of 1:2000 and incubation continued
overnight at 4 °C. Inactivated virus was then layered over a
20% sucrose gradient and pelleted by ultracentrifugation as
described above. The pelleted virus was resuspended in PBS
and stored in aliquots at −80 °C.
Virus concentration determination
The concentration of a virus standard was determined by
BCA kit (Pierce, Inc.). The BSA standard and the virus were
each prepared in detergent solution (final concentration 0.002%
NP-40, 0.0007% deoxycholate, 11 mM EDTA, 2 mM Tris–
HCl, 0.0002% protease inhibitor, 0.0002% SDS), incubated at
95 °C for 5 min and placed on wet ice immediately prior to
analysis. Subsequent lots of virus were analyzed by SDS-
PAGE and concentration relative to the virus standard was
determined.
Immunostaining
Expression of PA by the viral constructs SPBN-PA63 and
SPBN-PA63-TC was analyzed in BSR cells infected at an MOI
of 0.01 and incubated for 48 h, while expression of the D4-RV
G chimeras was analyzed in BSR cells infected at an MOI of 5
for 2 h with vaccinia virus expressing the T7 promoter (vVT7)
(Fuerst et al., 1986) followed by transfection with 5 μg pD4-
E439, pD4-E210, pD4-E127, pD4-E51 or pD4-ΔED using
calcium phosphate (Stratagene, Inc.). After 2 h incubation,
transfected cells were washed twice in DMEM and incubated
overnight in DMEM supplemented with 10% FBS. Cells were
fixed by incubation in 3% paraformaldehyde for 30 min at
room temperature followed by two washes in 10 mM glycine
in PBS (PBS-glycine). For internal staining, cells were
incubated in 1% Triton X-100 for 5 min at room temperature
followed by two washes in PBS-glycine. Cells were immu-
nostained with mouse anti-PA monoclonal antibody M2-V116
(OEM, Inc.) followed by FITC-labeled donkey anti-mouse IgG
(Jackson ImmunoResearch, Inc.) or FITC-labeled anti-RV
nucleoprotein (Centocor, Inc.).
Fluorescence-activated cell sortering (FACS) analysis
BSR cells were transfected with Bluescript SKII (Stratagene,
Inc.), pD4-E439, pD4-E210, pD4-E127, pD4-E51, or pD4-
ΔED as described above, washed once with PBS, detached
from the plate by treatment with 50 mM EDTA for 5 min at
room temperature, and washed twice in FACS buffer (2% FBS
in PBS). Cells were incubated with a 1:200 dilution of anti-PA
antibody M2-V116 in FACS buffer for 1 h at room temperature,
washed twice in FACS buffer, and further incubated with a
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(Jackson ImmunoResearch, Inc.). After two washes in FACS
buffer, cells were fixed in formaldehyde (Caltag GAS004 Fix
and Perm) for 15 min at room temperature, washed twice in
FACS buffer and analyzed by FACScan (Beckman Coulter XL
analyzer with a 488-nm argon ion laser).
SDS-PAGE and western blotting
BSR cells transfected overnight with plasmids pD4-E439,
pD4-E210, pD4-E127, pD4-E51 or pD4-ΔED as described
above, were washed twice with PBS and incubated with lysis
buffer (1% NP-40, 0.4% deoxycholate, 66 mM EDTA, 10 mM
Tris–HCL, protease inhibitor, 0.1% SDS) for 5 min on wet ice.
Lysates and purified virus were prepared for Western analysis
by adding protein-loading solution to a final concentration of
2% beta-mercaptoethanol and heating for 5 min at 95 °C.
Proteins were separated by 8% SDS polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred to a polyvinyl
difluoride membrane (Osmonics, Inc.). Blots were blocked
with 5% low-fat milk powder in PBS followed by incubation
with either a 1:2000 dilution of anti-PA M2-V116 or a
1:25,000 dilution of anti-RV G CD (Siler et al., 2002) in PBS
for 1 h at room temperature, and washed twice in 0.1% Tween-
20 in PBS (PBS-tween). Blots were probed with a 1:5000
dilution of HRP-conjugated donkey anti-mouse IgG (Jackson
ImmunoResearch, Inc.) or donkey anti-rabbit IgG (Jackson
ImmunoResearch, Inc.) and washed twice as described above.
Chemiluminescence was applied as instructed by the manu-
facturer (Sigma, Inc.).
Preparation of antigens for ELISAs and lymphocyte
proliferation assay
To generate RV G, virus was purified as described above.
Octyl β-D-glucopyranoside (Sigma) was added to a final
concentration of 1%. The material was centrifuged at
100,000×g at 15 °C for 1 h. RV G contained in the supernatant
was removed, diluted to 1 mg/ml in PBS and stored at −70 °C.
Viral ribonucleoprotein (RNP) was prepared as described
(Koser et al., 2004). All antigens were quantified by BCA kit
according to manufacturer's protocol (Pierce). Recombinant PA
was obtained from the Biodefense and Emerging Infections
Research Resources Repository (beiresources).
Immunization of mice
For comparison of live and killed vaccines, groups of five 6-
to 8-week-old Swiss Webster mice were immunized intramus-
cularly (i.m.) in the gastrocnemius with 50 μg of inactivated
SPBN-D4-E51, 3 × 106 focus-forming units (ffu) of live SPBN-
D4-E51, 50 μg of inactivated SPBN, or 3 × 106 ffu of live
SPBN. Mice were boosted as for primary inoculation 3 weeks
after first immunization and blood samples were obtained at
2 weeks after each inoculation.
For dose–response studies, groups of three 6- to 8-week-old
Swiss Webster mice were immunized i.m. in the gastrocnemiuswith 50 μg, 5 μg, 500 ng, 50 ng or 5 ng of inactivated SPBN-
D4-E51 or with 100 ng RV G + 100 ng rPA (List Biological
Laboratories, Inc.). Mice were boosted 3 weeks later and bled
2 weeks after each inoculation. In a second experiment, mice
were immunized as above with the same doses of inactivated
SPBN-D4-E51 or with 500 ng RV G + 500 ng rPA.
For lymphocyte proliferation analysis, groups of four 6- to 8-
week-old Swiss Webster mice were either left unimmunized or
immunized i.m. in the gastrocnemius with 50 μg of inactivated
SPBN-D4-E51 on days 0 and 21. At 4 weeks post-boost, mice
were sacrificed and spleens harvested.
All animal experiments were performed under IACUC-
approved protocols (AnimalWelfare Assurance No. A3085-01).
ELISAs
ELISA plates (96-well) were coated with 200 ng/well of
rPA (beiresources) or 100 ng/well RV G in coating buffer
(5 mM Na2CO3, pH 9.6) overnight at 4 °C. Plates were
washed four times in PBS-tween and blocked with 5% low-fat
milk in PBS for 1 h at room temperature. 100 μl sera diluted
in PBS as indicated in the figures were added to wells and
incubated for 1 h at room temperature. After washing plates 4
times in PBS-tween 100 μl HRP-conjugated donkey anti-
mouse IgG (Jackson ImmunoResearch, Inc.) diluted was
added per well and incubation continued at 37 °C for 30 min.
Plates were washed four times with PBS-tween before OPD
substrate prepared according to the manufacturer's instructions
(Sigma, Inc.), was added. Incubation was continued for
15 min at room temperature in the dark and the reaction
was stopped by adding 2 M H2SO4. Optical density at 490 nm
was determined.
Gamma-globulin subclass-specific ELISAs were performed
using one dilution series prepared for each of the three mice and
distributed to duplicate plates. Assays were performed as above,
using the secondary antibodies IgG1 (Southern Biotechnology,
Inc.) and IgG2a (Southern Biotechnology, Inc.) at 1:1500 and
1:1000 dilutions, respectively.
Lymphocyte proliferation assay
Single-cell suspensions from mouse spleens harvested 4
weeks post-boost were prepared by homogenization and
passage through a 100-μm cell strainer. Erythrocytes were
lysed and cells were washed and diluted in Iscove's modified
DMEM supplemented with 5% FCS. For each mouse,
2.5 × 106 cells/well were seeded in 24-well plates. Cells in
triplicate wells were stimulated with 0.3 μg RV G, 1 μg RV
RNP, 1 μg SPBN or 10 μg rPA. One set of wells without
antigen served as the medium control. At various time points,
100 μl of cells was removed to a 96-well plate and pulsed with
1 μCi of [3H]-thymidine. Cells were harvested 24 h later onto
glass fiber filter mats using a cell harvester (Skatron), placed in
scintillation vials with 3 ml scintillation fluid and assessed for
radioactivity in a scintillation counter. Average from triplicate
wells was calculated in counts per minute (CPM) and CPM of
the medium control subtracted for each antigen.
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